EGFR and non-small cell lung carcinoma: To accomplish this, we applied peptide mass fingerprinting using MALDI-TOF-MS coupled with ClinProTools software to analyze serum from 223 NSCLC patients with a known EGFR gene mutation status (i.e., determined by amplification refractory mutation system [ARMS] in tumor tissue) and detect differences in serum peptides/proteins between NSCLC patients with EGFR gene TKI-sensitive mutations and NSCLC patients with wild-type EGFR genes.